Cincinnati.Com
NKY.COM  |  ENQUIRER  |  CIN WEEKLY  |  Classifieds  |  Cars  |  Homes  |  Jobs  |  Help
Currently:
77°F
Partly Cloudy
Weather | Traffic
The Enquirer
HOME
NEWS
ENTERTAINMENT
SPORTS
REDS
BENGALS
LOCAL GUIDE
MULTIMEDIA
ARCHIVES
SEARCH
 
 TODAY'S ENQUIRER 
 Front Page 
-- Local News 
 Sports 
 Business 
 Editorials 
 Tempo 
 Home Style 
 Travel 
 Health 
 Technology 
 Weather 
 Back Issues 
 Search 
 Subscribe 

 SPORTS 
 Bearcats 
 Bengals 
 High School 
 Reds 
 Xavier 

 VIEWPOINTS 
 Jim Borgman 
 Columnists 
 Readers' views 

 ENTERTAINMENT 
 Movies 
 Dining 
 Horoscopes 
 Lottery Results 
 Local Events 
 Video Games 

 CINCINNATI.COM 
 Giveaways 
 Maps/Directions 
 Send an E-Postcard 
 Coupons 
 Visitor's Guide 

 CLASSIFIEDS 
 Jobs 
 Cars 
 Homes 
 Obituaries 
 General 
 Place an ad 

 HELP 
 Feedback 
 Subscribe 
 Search 
 Newsroom Directory 




 
Tuesday, January 23, 2001

FDA approves hepatitis drug




By Tim Bonfield
The Cincinnati Enquirer

        The first part of what doctors are calling a major advance in treatment for hepatitis C won approval Monday from the U.S. Food and Drug Administration.

        Hepatitis C is a potentially fatal liver disease caused by a viral infection that can develop for years before people realize they are sick. In Greater Cincinnati, a few thousand people have been diagnosed.

        On Monday, the FDA approved Peg-Intron, a once-a-week injection made by Schering-Plough Corp. that could replace a drug that requires injections three times a week.

        Doctors say the FDA action will become even more important in a few months if the agency also approves using the new product in combination with another drug, Ribavarin.

        “This is an important step in the next generation of treatment for hepatitis C,” said Dr. Kenneth Sherman, director of hepatology at the University of Cincinnati Medical Center. “We've had patients in Cincinnati getting the combination treatment (as part of a clinical trial) for almost two years. We're not calling it a cure. But we've seen sustained clearance in more than 50 percent of the patients.”

        That means the best tests were unable to detect the hepatitis C virus six months after treatment, Dr. Sherman said.

        Hepatitis C is spread through blood-to-blood contact. Intravenous drug users — including those who tried it only once — are the biggest risk group. Others risks include blood transfusions before 1991, tattoos or body piercings, and on-the-job exposure.

        For information about hepatitis C, call your doctor or the Hep C Connection Help Line, (800) 390-1202. A home test kit can be ordered via www.hepaware.com
       

       



Teachers working into pay-for-performance
Faith leads teens to capital protest
PULFER: Science textbooks don't tell whole story
Riverboat casinos pull in $497 million
Ind. gamblers might soon skip the cruise
UC going ahead with mansion over city's objection
Bengals withheld seats from sale
Death stalks Ross High
- FDA approves hepatitis drug
Health care tax apt to be on May ballot
Hospitals divvy up pediatric care
Man found dead after fire
Sex charges go back a decade
Slain woman's mother still seeking body
Firefighter saved from icy lake
Florence council hesitant to fund ballpark
Airport seeks grant for precision navigation
Awards recognize aid to handicapped
Four more charter schools for Cincinnati
High school revamp OK'd
Board to discuss role in adult education
Fire destroys Whitewater home
Fox blasts court, says it delays child cases
Indiana governor pushes daylight-saving time
Kentucky Digest
Local Digest
Monks show art at NKU
Where does electric power come from? Kids find out
Wife gets deal in pot case
Doctor pleads guilty to defrauding insurers
Ten Commandments donations dwindle
Workers' comp bill hits snag

 

Latest Headline News
Updated Every 30 Minutes
AP TOP HEADLINE NEWS

Iraqi Official: 150,000 Civilians Dead

Sen. Allen Concedes Defeat in Virginia

Bush, Pelosi Hold White House Talks

Massive Recall of Acetaminophen Underway

Mubarak Warns Against Hanging Saddam

Bolton Unlikely to Win Senate Approval

AP: Startling Findings in Tillman Probe

Ed Bradley of '60 Minutes' Dies at 65

U.S. Rises in Auto Reliability Ratings

49ers Look to Relocate New Stadium



Cincinnati.Com
Search our site by keyword:  
Search also: News | Jobs | Homes | Cars | Classifieds | Obits | Coupons | Events | Dining
Movies/DVDs | Video Games | Hotels | Golf | Visitor's Guide | Maps/Directions | Yellow Pages

  CINCINNATI.COM  |  NKY.COM  |  ENQUIRER  |  CIN WEEKLY  |  Classifieds  |  Cars  |  Homes  |  Jobs  |  Help


Search | Questions/help | News tips | Letters to the editors | Subscribe
Newspaper advertising | Web advertising | Place a classified | Circulation

Copyright 1995-2007. The Cincinnati Enquirer, a Gannett Co. Inc. newspaper.
Use of this site signifies agreement to terms of service updated 12/19/2002.